Vowles Zoë, Ashworth Danielle C, Barron Rebecca L, Conti-Ramsden Frances, Wilson Hannah, Leighton Lisa, Wall Louise, Walter Cherrelle, Myers Jenny, Chappell Lucy C
Department of Women's and Children's Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King's College London, St Thomas' Hospital, 10th Floor North Wing, London, SE7 8EH, UK.
Maternal and Fetal Health Research Centre, Saint Mary's Hospital, Manchester Foundation Trust, Manchester, UK.
Res Involv Engagem. 2024 Oct 7;10(1):101. doi: 10.1186/s40900-024-00634-7.
Both pregnant women and those with multiple long-term conditions are under-served groups in clinical research. Informing and improving research through patient and public involvement, including pregnant women with two or more long-term health conditions, is critical to increasing their inclusion in maternity research. Giant PANDA is a randomised controlled trial, evaluating the effect of a treatment initiation strategy with nifedipine versus labetalol on severe maternal hypertension and a composite outcome of fetal/neonatal death, or neonatal unit admission. We aimed to undertake a mixed methods study-within-a-project within the Giant PANDA trial to understand barriers and facilitators to participation, understand and optimise current representativeness of clinical trial delivery of those with multiple long-term conditions and co-create a checklist to support their inclusion in pregnancy research.
We undertook online workshops with women with lived experience and hybrid workshops with healthcare professionals who look after women with multiple long-term conditions. A site audit of Giant PANDA sites provided insights into research delivery capacity and health system set-up, and how this influences inclusion. An extension to the Giant PANDA screening log captured data on multiple long-term conditions enabling analysis of the impact of these health conditions on women's inclusion in the trial. We co-created a checklist of recommendations for those designing and recruiting to similar clinical trials.
Five key recommendations were identified including a need to (1) involve women with multiple long-term conditions as partners in maternity research and (2) minimise barriers that stop them from taking part through (3) designing and delivering research that is flexible in time and place (4) consider research as part of care for everyone, including those with multiple long-term conditions and (5) measure and report inclusion of those with two or more health conditions in maternity research. Multiple long-term conditions were not a barrier to recruitment or randomisation in the Giant PANDA trial.
Women with multiple long-term conditions would like opportunities to find out about and participate in research which accounts for their needs. Our checklist aims to support those designing and delivering maternity research to optimise inclusion of individuals with multiple-long term conditions.
Giant PANDA: EudraCT number: 2020-003410-12, ISRCTN: 12,792,616.
孕妇和患有多种慢性病的人群在临床研究中都是服务不足的群体。通过患者和公众参与(包括患有两种或更多慢性病的孕妇)来为研究提供信息并加以改进,对于提高她们在孕产妇研究中的参与度至关重要。“巨型熊猫”(Giant PANDA)是一项随机对照试验,评估硝苯地平与拉贝洛尔的治疗起始策略对重度孕产妇高血压以及胎儿/新生儿死亡或新生儿重症监护病房收治这一复合结局的影响。我们旨在开展一项在“巨型熊猫”试验项目内的混合方法研究,以了解参与的障碍和促进因素,理解并优化针对患有多种慢性病患者的临床试验实施的当前代表性,并共同制定一份清单以支持他们纳入妊娠研究。
我们与有实际经验的女性举办了线上研讨会,并与照顾患有多种慢性病女性的医疗保健专业人员举办了混合研讨会。对“巨型熊猫”试验点进行的现场审核提供了有关研究实施能力和卫生系统设置的见解,以及这如何影响纳入情况。对“巨型熊猫”筛查日志的扩展记录了有关多种慢性病的数据,从而能够分析这些健康状况对女性纳入试验的影响。我们共同为设计和招募类似临床试验的人员制定了一份建议清单。
确定了五项关键建议,包括需要(1)让患有多种慢性病的女性作为孕产妇研究的合作伙伴参与进来,以及(2)通过(3)设计和开展在时间和地点上灵活的研究,(4)将研究视为对每个人(包括患有多种慢性病的人)护理的一部分,以及(5)衡量并报告患有两种或更多健康状况的人在孕产妇研究中的纳入情况,来尽量减少阻碍她们参与的障碍。在“巨型熊猫”试验中,多种慢性病并非招募或随机分组的障碍。
患有多种慢性病的女性希望有机会了解并参与考虑到她们需求的研究。我们的清单旨在支持那些设计和开展孕产妇研究的人员,以优化患有多种慢性病个体的纳入情况。
“巨型熊猫”:欧洲药品管理局临床试验编号:2020 - 003410 - 12,国际标准随机对照试验编号:12,792,616。